Heplisav-B HBV vaccine for adults available in US

Dynavax announced in a recent press release its hepatitis B vaccine, Heplisav-B, is now available in the U.S.

“Dynavax is prepared and proud to launch our first product, Heplisav-B, in the United States,” Eddie Gray, CEO of Dynavax, said in the press release. “We believe the increase in the rate of infections and poor compliance with current three-shot regimens has the medical community eager for access to Heplisav-B for adults.”

Heplisav-B is the first new HBV vaccine for adults in the United Sates in more than 25 years, approved by the FDA on 9, 2017.

The vaccine can now be ordered through a network of distributors, which will continue to broaden. to the press release, Dynavax is currently working with an extensive network of group purchasing organizations and government entities to ensure all patients have access to Heplisav-B and has begun activities to support broad reimbursement through insurance plans.

Heplisav-B is a combination of HBV surface antigen with Dynavax’s proprietary Toll-like receptor 9 (TLR9) agonist, designed to enhance immune response. The treatment comprises two doses, with the second dose provided at 1 month.

Reference: www.dynavax.com

Dynavax announced in a recent press release its hepatitis B vaccine, Heplisav-B, is now available in the U.S.

“Dynavax is prepared and proud to launch our first product, Heplisav-B, in the United States,” Eddie Gray, CEO of Dynavax, said in the press release. “We believe the increase in the rate of infections and poor compliance with current three-shot regimens has the medical community eager for access to Heplisav-B for adults.”

Heplisav-B is the first new HBV vaccine for adults in the United Sates in more than 25 years, approved by the FDA on 9, 2017.

The vaccine can now be ordered through a network of distributors, which will continue to broaden. to the press release, Dynavax is currently working with an extensive network of group purchasing organizations and government entities to ensure all patients have access to Heplisav-B and has begun activities to support broad reimbursement through insurance plans.

Heplisav-B is a combination of HBV surface antigen with Dynavax’s proprietary Toll-like receptor 9 (TLR9) agonist, designed to enhance immune response. The treatment comprises two doses, with the second dose provided at 1 month.

Reference: www.dynavax.com